Sensorion (ALSEN) Corporate Presentation summary

Company vision and strategy

• Aims to transform the standard of care for hearing loss through advanced therapies, focusing on inner ear disorders and enabling unlimited connections for patients.

• Pursues a modality-agnostic approach, leveraging deep inner ear expertise and exclusive partnerships with leading institutions and companies.

• Targets a global franchise in hearing loss, with a diversified pipeline and strong presence in Europe, the US, and other regions.

• Backed by blue-chip life sciences investors, raising €100m since August 2023, ensuring cash runway through 2025.

• Experienced management and scientific team with significant gene therapy development expertise.

Pipeline and partnerships

• Pipeline includes two gene therapies: SENS-501 (Otoferlin deficiency, Ph1/2 approved) and GJB2-GT (Connexin 26 deficiency, clinic entry in 2025).

• SENS-401, a small molecule, is in Phase 2a for cochlear implantation and cisplatin-induced ototoxicity, with Phase 2b completed for sudden sensorineural hearing loss (SSNHL).

• Collaborates with Institut Pasteur, Necker Hospital, Cochlear Ltd, Sonova, and others for research, clinical studies, and patient access.

• Natural history studies and patient registries are ongoing to support clinical development and regulatory engagement.

• 3SBio holds rights of first refusal for SENS-401 and SENS-501 in Greater China (excluding cochlear implant combinations).

Gene therapy programs

• SENS-501 targets pediatric patients with OTOF mutations, aiming for best-in-class efficacy and safety; first patient communication expected H2 2024.

• SENS-501 demonstrated durable hearing restoration in preclinical models and has orphan drug and rare pediatric disease designations in the US and EU.

• GJB2-GT addresses multiple forms of hearing loss linked to GJB2 mutations, with a lead candidate showing safety, targeted delivery, and prevention of hearing loss in animal models.

• GJB2-GT clinical trial applications planned for mid-2025, with ongoing natural history studies in collaboration with Sonova.

• Proprietary surgical approaches and injection devices developed to optimize gene therapy delivery.